2020
Clinical implication of serum CA125 for the prediction of malignancy in mucinous cystic neoplasms of the pancreas
Deng S, Fan Z, Gong Y, Cheng H, Jin K, Qian Y, Xiao Z, Liu Y, Wang R, Zheng Y, Ni Q, Yu X, Liu C, Luo G. Clinical implication of serum CA125 for the prediction of malignancy in mucinous cystic neoplasms of the pancreas. Experimental And Therapeutic Medicine 2020, 20: 158. PMID: 33093896, PMCID: PMC7571373, DOI: 10.3892/etm.2020.9287.Peer-Reviewed Original ResearchMucinous cystic neoplasmsSerum CA125Carcinoembryonic antigenMalignant changeReceiver operating characteristicCystic neoplasmsCarbohydrate antigenPredictive value of CA125Serum carbohydrate antigenSerum carcinoembryonic antigenPredictive of malignancyValue of CA125CA19-9Predicting malignancyMalignant potentialInvasive groupSerum levelsCA125Grade groupPredictive valueSerumPredictive roleHigh gradeClinical implicationsAntigen
2016
Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping
Luo G, Guo M, Jin K, Liu Z, Liu C, Cheng H, Lu Y, Long J, Liu L, Xu J, Ni Q, Yu X. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. Pancreatology 2016, 16: 1057-1062. PMID: 27692554, DOI: 10.1016/j.pan.2016.09.013.Peer-Reviewed Original ResearchConceptsDetect pancreatic cancerCut-off valueSensitivity of CA19-9CA19-9Pancreatic cancerEffectiveness of CA19-9Secretor genotypeStaging of pancreatic cancerII pancreatic cancerDetection of stage INegative predictive valueCohort of subjectsCA19Carbohydrate antigenStage IPredictive valueSanger sequencingCancerSecretor statusSecretorEarly detectorGenotypic backgroundGroup